📰 Tom Riga News
Tom Riga News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Tom Riga. Real-time updates on events, politics, business and more.
February 29, 2024
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 –
August 4, 2023
Operator: Good morning, and welcome to the Assertio Holdings Inc Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in -a listen-only mode.
May 9, 2023
-- Q1 2023 net sales of $15.6 million, an increase of 54% compared to Q4 2022 -- -- Company to be acquired by Assertio Holdings, Inc., delivering value to stakeholders in an all stock and... | May 9, 2023
April 25, 2023
Assertio Holdings and Spectrum Pharmaceuticals Transaction April 25, 2023 Corporate Speakers · ... | April 25, 2023
April 25, 2023
Spectrum Pharmaceuticals is a commercial-stage biopharmaceutical company focused on novel and targeted oncology.
March 24, 2023
Operator: Good day and thank you for standing by. Welcome to the Spectrum Pharmaceuticals 4Q 2022 Earnings Call. At this time, all participants are in a listen-only mode.
January 31, 2023
31.01.2023 - Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology, today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022. Business ... Seite 1
November 29, 2022
The FDA has issued a complete response letter to Spectrum Pharmaceuticals regarding the new drug application for poziotinib.
November 28, 2022
The FDA has issued a Complete Response Letter to Spectrum Pharmaceuticals regarding the New Drug Application for poziotinib.
November 25, 2022
The drug was not approved for the treatment of patients with previously treated locally advanced or metastatic nonsmall cell lung cancer harboring HER2 exon 20 insertion mutations.